BCC Research Publishes New Report on Global Market For Dna Sequencing Products
The global market for DNA sequencing products and services was valued at $3.5 billion in 2012 and was estimated at nearly $4.5 billion for 2013. BCC Research expects the market to grow to nearly $11.7 billion by 2018, and register a five-year compound annual growth rate of 21.2% from 2013 to 2018.
Wellesley, Mass. (PRWEB) February 24, 2014
According to a new technical market research report DNA Sequencing: Emerging Technologies and Applications, from BCC Research (http://www.bccresearch.com), the global market for DNA sequencing products and services was valued at $3.5 billion in 2012 and was estimated at nearly $4.5 billion for 2013. BCC Research expects the market to grow to nearly $11.7 billion by 2018, and register a five-year compound annual growth rate of 21.2% from 2013 to 2018.
The Human Genome Project (HGP) moved DNA sequencing technology to the forefront of life science research as a genetic analysis tool. HGP relied heavily on Sanger sequencing by capillary electrophoresis to decipher the DNA sequence of the bases in the human genome. Consequently, it led to significant improvements in the efficiency and costs of DNA sequencing. During this time period, the sequencing industry consolidated, resulting in one dominant company, Applied Biosystems (now Life Technologies).
Beginning in 2005, the launch of next-generation sequencing (NGS) technologies radically changed the structure of the industry and opened up exciting new market applications. The costs of sequencing have rapidly reduced to the point where it is now feasible for complex NGS tests to be priced in the range of other multiplex genetic tests. As a result, opportunities for sequencing products and services are emerging in diverse applications ranging, for example, from clinical diagnostics to direct to consumer genetic testing markets.
Clinical value has been shown for many applications, and several launched tests are having good commercial success. This shows that both patients and physicians are recognizing the value of NGS tests. At the same time, payors and insurance companies are beginning to provide coverage for these tests, further enhancing their commercial potential. In direct to consumer genetic testing market, there is an emerging trend to move to sequencing of specific genome regions. Compared with microarrays, sequencing provides more comprehensive information to the consumer. These technical and market factors are driving the sequencing markets and it is now timely to examine this market and these factors in detail.
This technical market research report from BCC Research provides an overview of DNA sequencing technologies, applications, industries, initiatives, markets, patents and companies. The markets for sequencing products and services are given for the years 2012, 2013 and 2018. It reviews the main sequencing platforms, and explains why genetic variation is important for many markets, including clinical testing. It then discusses some of the top research initiatives that are contributing to NGS applications. Market driving forces are also discussed.
In addition, the report covers the sequencing markets by work flow, including sample preparation products; sequencing instruments & consumables; informatics; and sequencing services. It includes the sequencing instrument market by platform: Sanger, NGS and third generations sequencing (3GS) and by instrument class: low throughput, high-throughput, benchtop, and handheld. It also assesses the markets for the main sequencing end-use applications, including research (R&D, drug discovery & development, biotech); clinical; consumer; and applied (forensics, microbial genomics, agricultural genomics). A key part of the report covers NGS clinical markets in depth, including by test complexity, indication and test purpose.
This report is a useful guide for strategic and business planning, as well as for learning about the impact new sequencing technologies will have in the various market segments. It will be useful to many companies involved in the direct to consumer, informatics, clinical, genetic testing and sequencing industries. In addition, this study will be particularly valuable for companies in such industries as life science research tools, NGS instruments, molecular diagnostics, informatics, clinical laboratories, pharmaceutical, biotechnology, microfluidics, lab-on-a-chip, and sample preparation.
For the original version on PRWeb visit: http://www.prweb.com/releases/2014/02/prweb11610308.htm